Immediate Impact
3 from Science/Nature 76 standout
Citing Papers
Oesophageal cancer
2024 Standout
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
2023 Standout
Works of Marie‐Laure Risse being referenced
Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors
2000
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
2000
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Marie‐Laure Risse | 297 | 474 | 418 | 40 | 710 | |
| Shuanglian Li | 119 | 415 | 253 | 29 | 777 | |
| C Ardiet | 95 | 316 | 234 | 37 | 670 | |
| Sophie Broutin | 97 | 299 | 208 | 47 | 757 | |
| Susan M. Christner | 106 | 312 | 321 | 32 | 706 | |
| R. Sridhara | 87 | 367 | 197 | 24 | 845 | |
| Carl G. Schmidt | 139 | 264 | 349 | 32 | 790 | |
| Mark DeMario | 81 | 398 | 431 | 25 | 794 | |
| Angela Gernone | 269 | 263 | 337 | 32 | 770 | |
| Juan Eduardo Megías‐Vericat | 345 | 179 | 234 | 60 | 776 | |
| Yoshiaki Okuno | 276 | 243 | 229 | 40 | 781 |
All Works
Login with ORCID to disown or claim papers
Loading papers...